Because ASCT2 expression contributes to cell growth, this raises the possibility that drugs targeting ASCT2, or more broadly cellular glutamine uptake or downstream glutamine enzymes, could be utilised as a therapeutic strategy for the treatment of endometrial carcinoma. Here, SLC1A5 is linked to endometrial carcinoma.